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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S162stresses is reduced due to tissue removed. Impaired knee function, such as
poor self-reported outcomes, muscle weakness and reduced functional
performance is other suggested factors that may contribute to progression
of knee OA. This study aimed to examine pre-operative knee function in
middle-aged female and male patients with degenerative meniscus tears
eligible for arthroscopic surgery, compared to a healthy population and the
respective patient non-injured leg.
Methods: 70 patients (36% females, age (meanSD) 496, BMI 273) with
an MRI veriﬁed degenerative meniscal tear considered eligible for surgery
were included. Outcomemeasures were the Knee injury and Osteoarthritis
Outcome Score (KOOS), isokinetic knee extension and ﬂexion muscle
strength tests and three lower extremity performance tests; maximum
number of kneebendings in 30s, the one leg hop for distance and the 6-
meter timed hop test. The performance tests are in addition to muscle
strength also dependent on the ability to switch between concentric and
eccentric muscle contraction, balance and functional stability, and for the
hop tests conﬁdence in the knee.
Results: KOOS mean subscale scores ranged from 43 to 76. Mean score
differences between the patients and an age matched population based
reference group ranged from 13 to 38 (p¼<0.000), Figure 1. There were no
signiﬁcant differences in KOOS scores between genders. The index leg was
signiﬁcantly weaker in isokinetic knee extension and ﬂexion strength
compared to the contralateral leg (155Nm53 and 84Nm27 vs.
179Nm51 and 87Nm24, p 0.03). Mean differences in peak torque and
total work quadriceps muscle strength compared with the contralateral
leg was 15% and 14% for the females and 13% and 9% for the males,
respectively. For all three lower extremity performance tests the results of
the index leg were signiﬁcantly worse than for the contralateral leg
(number of kneebendings 2610 vs. 2810, p¼<0.001, one leg hop 8235
vs. 9231 cm p¼<0.001, 6-meter timed hop test 3.01.4 vs. 2.50.8 s,
p¼<0.001). Mean differences in the three tests compared with the
contralateral leg ranged from 12% to 14% for the females and 5% to 12% for
the males.
Conclusions: Patients with a degenerative meniscus tear considered
eligible for surgery reported severely impaired pain, other symptoms,
function in daily living and sports, and knee related quality of life
compared to an age matched population based reference group. Muscle
function in the index leg was signiﬁcantly worse with up to 15% lower
muscle function compared to the contralateral leg. These results suggest
that risk factors for OA onset, other than intraarticular damage, are present
in patients with a degenerative meniscus tear.
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FUNCTION
L. Klokker Madsen 1, R. Osborne 2, H. Bliddal 1,3, M. Henriksen 1. 1 Parker
Inst., Copenhagen, Denmark; 2 Population Hlth.Strategic Res. Ctr., Sch. ofHlth.and Social Dev., Deakin Univ., Burwood, Australia; 3 Faculty of
Hlth.Sci., Univ. of Copenhagen, Copenhagen, Denmark
Purpose: Measures of pain and function are core outcomes in knee oste-
oarthritis (OA) in both clinical practice and research. In order to evaluate
treatment effects the target construct of an outcome measure must
correspond to the target of treatment, which in pharmacological and
exercise based treatment of knee OA primarily is a sensory aspect of pain.
Functional Pain Measure (FPM) is a novel method to assess pain in knee
OA, which is proposed to target a sensory aspect of pain by use of a pain
provoking function with a subsequent pain rating. This proof of concept
study aimed to explore the patient perspective with respect to face and
content validity of FPM, clinical relevance and psychological process of
response, and to evaluate the interpretability of results and the feasibility
in clinical practice and research settings.
Methods: In this cross sectional mixed method study, 10 patients with
knee OA walked on a treadmill for 10-20 minutes with self-reported
habitual speed, determined before the test. Target knee pain (most
symptomatic knee) was rated verbally before, every 3 minutes during and
5 minutes after walking, on a 21 point numeric rating scale (NRS, 0¼no
pain, 10¼worst pain imaginable). Individual semi structured interviews
were conducted, exploring the patient's experience of the walking task,
pain and function, reﬂections of rating pain, attitudes towards different
rating scales presented (e.g. visual analog scale, statements of pain
severity, emoticons), and relevant emergent themes. The Pain Detect
questionnaire, an instrument used to estimate the likelihood of a neuro-
pathic pain component, was completed. Data were analyzed by content
analysis and descriptive statistics. Interpretability and feasibility were
evaluated using qualitative thematic analysis.
Results: All but 2 participants experienced pain before, during or after the
walking task, as seen in ﬁgure 1. Comparison of mean NRS during walking
and Pain Detect scores shows a trend of increased likelihood of a neuro-
pathic pain component with higher pain ratings (ﬁgure 2). Generally the
participants found that the walking task imitated their habitual walking
pain, and expressed an increased attention to the knee pain during the test.
Some participants found this attention helpful in the process of rating their
pain, compared to recalling pain when ﬁlling out a questionnaire. All
participants were positive towards the walking task and the NRS as a pain
rating scale, and welcomed a possible implementation of FPM in clinical
practice and research, although one participant experienced increased
pain one week after the test (opposite knee). The test is simple to conduct,
requires standard clinical skills and would be easy to implement, although
limited access to a treadmill and restricted time resources might be
barriers.
Conclusions: The ﬁndings suggest the FPM is a promising assessment with
patient perceived face and content validity. There are indications of good
concurrent validity of the FPM in relation to neuropathic pain. Ongoing
development of FPM will include reﬁning processes to increase feasibility
and safety, and to establish reliability and sensitivity to change.
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G.E. Ahn 1, J. Song 1, J. Lee 1, P.A. Semanik 1, R.W. Chang 1, L. Sharma 1,
C.B. Eaton 2, R.D. Jackson 3, A. Mysiw 4, D. Dunlop 1. 1Northwestern Univ.,
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Purpose: Physical activity conveys health beneﬁts for people with osteo-
arthritis (OA). Epidemiological studies often use self-reported instruments
to explore this relationship, but these measures do not effectively capture
actual time spent in physical activity in varying intensities. Public health
physical activity guidelines are tied to time spent in physical activity of
moderate/vigorous intensity. This study utilizes accelerometers to objec-
tively assess time spent in moderate/vigorous physical activity (MVPA) in
adults with knee OA.We investigated the correlation of objectivemeasures
with less burdensome subjective measures from Physical Activity Scale in
the Elderly (PASE) scores. We also evaluated the association of subjective
and objective measures to physical function.
Methods: Cross-sectional accelerometer data from 969 adults aged 55 and
above with radiographic knee OA (Kellgren-Lawrence  2 in one or both
knees) participating in the Osteoarthritis Initiative accelerometer moni-
toring ancillary study was assessed for physical activity and function.
Participants’ response to the PASE questionnaire was followed by 7 days of
accelerometer monitoring. Accelerometer measures included average
daily minutes in MVPA and average daily minutes in MVPA sessions of 10
minutes or more (MVPA bouts). Other subjective measures including
WOMAC (Western OntarioMacMaster) function, SF12 (12-Item Short Form
Health Survey) physical function, objective measure gait speed averaged
from two 20 meter walks, and covariables including demographics (age,
gender), and heath factors (BMI and waist circumference) were assessed.
Results:Mean PASE score was 149.80 (SD¼78.4) and mean accelerometer
MVPA was 15.55 minutes/day (SD¼17.18). PASE scores were modestly
correlated with average daily minutes in MVPA (r¼0.31) and MVPA bouts
(r¼0.21). PASE scores correlated better with accelerometer measures of
MVPA and MVPA bouts in participants who were particularly inactive
(characterized by older age, higher BMI, and greater waist circumference).
There were no signiﬁcant gender effects. Accelerometer measures of MVPA
and MVPA bouts compared to PASE scores had stronger correlation in
WOMAC function (r:-0.14, -0.12 versus -0.02), SF12 physical function
(r: 0.22, 0.19, versus 0.07), and gait speed (r: 0.35, 0.29, versus 0.16).
Conclusions: In this population with radiographic knee OA, modest
correlations of PASE with accelerometer MVPA assessments limit the
ability to use this self-reported instrument to explore relationships ofactivity intensity and OA. Accelerometry data are complementary and help
to better characterize the effects of physical activity on health outcomes.
Accelerometer MVPA and MVPA bouts were more strongly associated with
physical function than PASE, although that correlation was modest at best.
The choice of PASE versus objectivemeasurement for future epidemiologic
studies must take into account the purpose for which physical activity is
being measured.
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OSTEOARTHRITIS IN FRANCE THE COST OF AMBULATORY CARE IN 2010
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Purpose: In France, the cost of an osteoarthritic patient has not been
estimated for several years. The aim of the study was to evaluate the
annual cost of the treatment given to osteoarthritic patients by GP.
Methods: The cohort was made up of patients who were diagnosed with
osteoarthritis between April 2009 and March 2010 (IMS Disease Analyzer
database) The cost includes all medical cost to the patients in the cohort,
and colligated in the Disease Analyzer database (all consultations with GPs
and all resulting drug prescriptions). The evaluated cost is therefore the
annual cost of treatment given to an osteoarthritic patient.
Results: 18 976 patients suffering from osteoarthritis were followed. For
these patients, who had an average age of 66, all consultations with GPs as
well as all resulting drug prescriptions were valued both in terms of
societal cost and cost to health insurance. The average annual cost of
disease management by a GP of a patient suffering from osteoarthritis is
therefore valued at V755 societal cost, of which around 60% (V447) is paid
by health insurance. The annual cost of treatment by a GP of a patient
suffering from hip osteoarthritis is signiﬁcantly lower at the societal level
(V715) than at the health insurance level (V425) compared to patients
suffering from osteoarthritis in the knee or elsewhere, despite their higher
age.
Conclusions: No literary data evaluating the cost of an osteoarthritic
patient currently exists. The closest data is that produced by a COART
France study (Le Pen and coll, Revue du rhumatisme, December 2005). The
prevalence of osteoarthritis has been estimated at around 4 million
sufferers, even though this ﬁgure may be conservative, we can estimate
that the cost of osteoarthritis treatment is around 3 billion euros. We are
sure that further data will be added to existing ones.
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INCIDENCE, RISK FACTORS AND CONSEQUENCES OF PERIPROSTHETIC
AND FEMORAL FRACTURE AMONG THOSE WHO SURVIVED TOTAL HIP
REPLACEMENT FOR MORE THAN A DECADE
J.N. Katz, E.A. Wright, M.B. Harris, E. Losina. Brigham and Women's Hosp.,
Boston, MA, USA
Purpose: To determine the incidence and risk factors for periprosthetic
and non-periprosthetic femoral fractures, as well as the risk of subsequent
hospitalization following these fractures, for a population-based cohort of
patients who had a total hip replacement (THR) in 1995-1996 and were
followed from 2006-2008.
Methods:We used Medicare claims data to assemble a cohort of Medicare
beneﬁciaries who had elective primary THR from July, 1995 through June,
1996. We obtained Medicare hospital claims for these patients through
2008. The ICD-9-CM code for periprosthetic fracture (996.44) was intro-
duced in October, 2005. We excluded periprosthetic fractures occurring in
the knee or shoulder region. We used the incidence density method to
calculate the annual incidence of each fracture. Time ‘at risk’ was deﬁned
from the beginning of observation (January 2006) to one of the three
events, whichever occurred ﬁrst: 1) death, 2) fracture or 3) end of the
observation period (December 2008). We used multivariate Cox propor-
tional hazards models to identify risk factors for periprosthetic fractures
and for non-implant related femoral fractures, including sex, age, race,
number of non-elective hospitalizations in the prior decade (a proxy for
comorbidity), eligibility for Medicaid (a proxy for low income) and number
